(19)
(11) EP 2 308 546 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.10.2014 Bulletin 2014/42

(45) Mention of the grant of the patent:
27.06.2012 Bulletin 2012/26

(21) Application number: 10187042.6

(22) Date of filing: 08.10.2010
(51) International Patent Classification (IPC): 
A61M 37/00(2006.01)

(54)

Transmucosal drug delivery device and method including microneedles

Vorrichtung zur transmukosalen Arzneimittelverabreichung und Verfahren mit Mikronadeln

Dispositif d'administration transmucosale de médicament et procédé incluant des micro-aiguilles

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 08.10.2009 US 576075

(43) Date of publication of application:
13.04.2011 Bulletin 2011/15

(73) Proprietor: Palo Alto Research Center Incorporated
Palo Alto, CA 94304 (US)

(72) Inventors:
  • Uhland, Scott
    San Jose, CA 95125 (US)
  • Peeters, Eric
    Mountain View, CA 94043 (US)

(74) Representative: Jones, Helen M.M. 
Gill Jennings & Every LLP The Broadgate Tower 20 Primrose Street
London EC2A 2ES
London EC2A 2ES (GB)


(56) References cited: : 
WO-A1-2007/041119
US-A1- 2008 004 596
 US-A1- 2004 087 893
US-A1- 2009 171 315
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).